Skip to content

Study · Systematic review · 2023

7 results

Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis

Yu D, Shen S, Zhang J, Wang Q

Clinical therapeutics14 Jul 2023Cited by 8 (Europe PMC)

PMID37455226 (opens in a new tab)DOI10.1016/j.clinthera.2023.06.008 (opens in a new tab)PepBankPUB-37455226
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults in randomized trials, tirzepatide 5, 10 and 15 mg changed total cholesterol from baseline compared with control agents (P < 0.05); the abstract wording on direction is unclear.

    In plain wordsIn adults in trials, tirzepatide changed total cholesterol compared with control drugs; the abstract does not state the direction clearly.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedTotal cholesterol change from baseline
    Study

    n: not reported in source

    Comparator
    Placebo, semaglutide, dulaglutide, degludec
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    5, 10 and 15 mgAs given in this study (human).

    Source sentences

    Summary
    All 3 eligible maintenance doses of tirzepatide (5, 10, and 15 mg once a week) were effective in increasing total cholesterol (TC) (P < 0.05), HDL-C (P < 0.05), VLDL-C (P < 0.01), triglyceride (TG) (P < 0.01), and WC (P < 0.01) changes from baseline compared with control agents including placebo, se…
    1 context sentence
    Summary · context
    This meta-analysis included 7 randomized controlled trials with a minimum duration of 12 weeks that compared tirzepatide with placebo or other antidiabetic medications.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults in randomized trials, tirzepatide 5, 10 and 15 mg changed HDL cholesterol from baseline compared with control agents (P < 0.05); the abstract wording on direction is unclear.

    In plain wordsIn adults in trials, tirzepatide changed HDL (good) cholesterol compared with control drugs; the abstract does not state the direction clearly.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedHDL cholesterol change from baseline
    Study

    n: not reported in source

    Comparator
    Placebo, semaglutide, dulaglutide, degludec
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    5, 10 and 15 mgAs given in this study (human).

    Source sentences

    Summary
    All 3 eligible maintenance doses of tirzepatide (5, 10, and 15 mg once a week) were effective in increasing total cholesterol (TC) (P < 0.05), HDL-C (P < 0.05), VLDL-C (P < 0.01), triglyceride (TG) (P < 0.01), and WC (P < 0.01) changes from baseline compared with control agents including placebo, se…
    1 context sentence
    Summary · context
    This meta-analysis included 7 randomized controlled trials with a minimum duration of 12 weeks that compared tirzepatide with placebo or other antidiabetic medications.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults in randomized trials, tirzepatide 5, 10 and 15 mg changed VLDL cholesterol from baseline compared with control agents (P < 0.01); the abstract wording on direction is unclear.

    In plain wordsIn adults in trials, tirzepatide changed VLDL cholesterol compared with control drugs; the abstract does not state the direction clearly.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedVLDL cholesterol change from baseline
    Study

    n: not reported in source

    Comparator
    Placebo, semaglutide, dulaglutide, degludec
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    5, 10 and 15 mgAs given in this study (human).

    Source sentences

    Summary
    All 3 eligible maintenance doses of tirzepatide (5, 10, and 15 mg once a week) were effective in increasing total cholesterol (TC) (P < 0.05), HDL-C (P < 0.05), VLDL-C (P < 0.01), triglyceride (TG) (P < 0.01), and WC (P < 0.01) changes from baseline compared with control agents including placebo, se…
    1 context sentence
    Summary · context
    This meta-analysis included 7 randomized controlled trials with a minimum duration of 12 weeks that compared tirzepatide with placebo or other antidiabetic medications.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults in randomized trials, tirzepatide 5, 10 and 15 mg changed triglycerides from baseline compared with control agents (P < 0.01); the abstract wording on direction is unclear.

    In plain wordsIn adults in trials, tirzepatide changed triglycerides compared with control drugs; the abstract does not state the direction clearly.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedTriglyceride change from baseline
    Study

    n: not reported in source

    Comparator
    Placebo, semaglutide, dulaglutide, degludec
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    5, 10 and 15 mgAs given in this study (human).

    Source sentences

    Summary
    All 3 eligible maintenance doses of tirzepatide (5, 10, and 15 mg once a week) were effective in increasing total cholesterol (TC) (P < 0.05), HDL-C (P < 0.05), VLDL-C (P < 0.01), triglyceride (TG) (P < 0.01), and WC (P < 0.01) changes from baseline compared with control agents including placebo, se…
    1 context sentence
    Summary · context
    This meta-analysis included 7 randomized controlled trials with a minimum duration of 12 weeks that compared tirzepatide with placebo or other antidiabetic medications.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults in randomized trials, tirzepatide 5, 10 and 15 mg changed waist circumference from baseline compared with control agents (P < 0.01); the abstract wording on direction is unclear.

    In plain wordsIn adults in trials, tirzepatide changed waist size compared with control drugs; the abstract does not state the direction clearly.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedWaist circumference change from baseline
    Study

    n: not reported in source

    Comparator
    Placebo, semaglutide, dulaglutide, degludec
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5, 10 and 15 mgAs given in this study (human).

    Source sentences

    Summary
    All 3 eligible maintenance doses of tirzepatide (5, 10, and 15 mg once a week) were effective in increasing total cholesterol (TC) (P < 0.05), HDL-C (P < 0.05), VLDL-C (P < 0.01), triglyceride (TG) (P < 0.01), and WC (P < 0.01) changes from baseline compared with control agents including placebo, se…
    1 context sentence
    Summary · context
    This meta-analysis included 7 randomized controlled trials with a minimum duration of 12 weeks that compared tirzepatide with placebo or other antidiabetic medications.
  6. 06HumanSystematic reviewEfficacy outcome

    In adults in randomized trials, only tirzepatide 5 mg once weekly induced a significant alteration in LDL cholesterol before sensitivity analysis (P < 0.05).

    In plain wordsIn adults in trials, only tirzepatide 5 mg significantly changed LDL (bad) cholesterol, before sensitivity analysis.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedLDL cholesterol change, 5 mg
    Study

    n: not reported in source

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    5 mgAs given in this study (human).

    Source sentences

    Summary
    Only 5mg once-weekly tirzepatide (P < 0.05), not 10 or 15 mg, could induce significant alteration in LDL-C before sensitivity analysis.
    1 context sentence
    Summary · context
    This meta-analysis included 7 randomized controlled trials with a minimum duration of 12 weeks that compared tirzepatide with placebo or other antidiabetic medications.
  7. 07HumanSystematic reviewEfficacy outcome

    In adults in randomized trials, tirzepatide 10 mg and 15 mg did not induce a significant alteration in LDL cholesterol before sensitivity analysis.

    In plain wordsIn adults in trials, tirzepatide 10 mg and 15 mg did not significantly change LDL (bad) cholesterol, before sensitivity analysis.

    Peptide
    Tirzepatide
    Outcome
    No significant changeLDL cholesterol change, 10 mg and 15 mg
    Study

    n: not reported in source

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    10 mg and 15 mgAs given in this study (human).

    Source sentences

    Summary
    Only 5mg once-weekly tirzepatide (P < 0.05), not 10 or 15 mg, could induce significant alteration in LDL-C before sensitivity analysis.
    1 context sentence
    Summary · context
    This meta-analysis included 7 randomized controlled trials with a minimum duration of 12 weeks that compared tirzepatide with placebo or other antidiabetic medications.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.